| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MCL1 |
| Uniprot No | Q07820 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-327aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MFGLKRNAVI GLNLYCGGAG LGAGSGGATR PGGRLLATEK EASARREIGG GEAGAVIGGS AGASPPSTLT PDSRRVARPP PIGAEVPDVT ATPARLLFFA PTRRAAPLEE MEAPAADAIM SPEEELDGYE PEPLGKRPAV LPLLELVGES GNNTSTDGSL PSTPPPAEEE EDELYRQSLE IISRYLREQA TGAKDTKPMG RSGATSRKAL ETLRRVGDGV QRNHETAFQG MLRKLDIKNE DDVKSLSRVM IHVFSDGVTN WGRIVTLISF GAFVAKHLKT INQESCIEPL AESITDVLVR TKRDWLVKQR GWDGFVEFFH VEDLEGG |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MCL1 Recombinant Protein**
MCL1 (myeloid cell leukemia 1) is a critical anti-apoptotic member of the BCL-2 protein family, playing a pivotal role in regulating programmed cell death. It is essential for maintaining mitochondrial integrity by binding and neutralizing pro-apoptotic proteins like BAX and BAK, thereby preventing cytochrome c release and caspase activation. Overexpression of MCL1 is frequently observed in various cancers, including hematologic malignancies and solid tumors, and is linked to tumor survival, chemoresistance, and poor prognosis. This makes MCL1 a compelling therapeutic target.
Recombinant MCL1 protein is generated through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells), enabling large-scale production of the purified protein for functional and structural studies. Its recombinant form retains the conserved BCL-2 homology (BH) domains required for interactions with apoptotic regulators. Researchers utilize MCL1 recombinant protein to study its biochemical properties, screen for inhibitors, and elucidate mechanisms of apoptosis evasion.
In drug discovery, MCL1 inhibitors are being actively developed to disrupt its interaction with pro-apoptotic partners, aiming to restore apoptosis in cancer cells. However, challenges remain, including achieving selectivity over other BCL-2 family members and mitigating off-target effects. Structural studies using recombinant MCL1. such as X-ray crystallography or NMR, have provided insights into its 3D conformation and binding pockets, guiding rational drug design.
Additionally, recombinant MCL1 is employed in diagnostic assays to quantify expression levels in clinical samples, aiding in cancer stratification and monitoring therapeutic responses. Its role in non-cancer contexts, such as immune regulation and tissue homeostasis, is also under exploration.
Overall, MCL1 recombinant protein serves as a vital tool for understanding apoptosis dysregulation in diseases and advancing targeted therapies, though balancing efficacy and toxicity remains a key focus in translational research.
×
